Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
The development and regulatory approval of vemurafenib and dabrafenib for metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive disease. However, these agents are n...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Advocate Aurora Health
2014-01-01
|
| Saila: | Journal of Patient-Centered Research and Reviews |
| Gaiak: | |
| Sarrera elektronikoa: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1006&context=jpcrr |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|